23 . 10 .2025
Press release
Galderma delivers record net sales of 3.737 billion USD in the first nine months of 2025 and 15.0% year-on-year growth at constant currency, raises full-year guidance
24 . 07 .2025
Press release
Galderma delivers record first half 2025 net sales of 2.448 billion USD and 12.2% year-on-year growth at constant currency, raises full-year top-line guidance
28 . 05 .2025
Press release
Galderma buys back shares worth CHF 233 million in the context of accelerated bookbuild offering
27 . 05 .2025
Press release
Galderma intends to buy back approximately 2.4 million shares in the context of the accelerated bookbuild offering by EQT, ADIA and Auba
24 . 04 .2025
Press release
Galderma delivers record first quarter net sales of 1.129 billion USD, including strong performance from two launches with blockbuster potential, and confirms full-year guidance
21 . 03 .2025
Press release
Galderma publishes its 2024 Annual Report and the invitation to its first Annual General Meeting
06 . 03 .2025
Press release
Galderma delivers 2024 record net sales of 4.410 billion USD, up 9.3% year-on-year at constant currency1, and record Core EBITDA of 1.031 billion USD, while preparing to accelerate its growth trajectory into 2025 and beyond
14 . 02 .2025
Press release
Galderma’s Nemluvio® (nemolizumab) approved in the European Union for moderate-to-severe atopic dermatitis and prurigo nodularis
14 . 12 .2024
Press release
Galderma Receives U.S. FDA Approval for Nemluvio® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis